News
IMPACT-1 was a randomized, double-blind, placebo-controlled, Phase 2 clinical trial evaluating TSND-201 (methylone), a rapid-acting neuroplastogen, for the treatment of PTSD. This study enrolled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback